Want to see DWTX full AI Analyst Report?
DWTX Stock Chart & Stats
$3.15
-$0.11(-4.15%)
At close: 4:00 PM EST
$3.15
-$0.11(-4.15%)
Day’s Range― - ―
52-Week Range$1.28 - $9.50
Previous CloseN/A
Volume14.38K
Average Volume (3M)1.54M
Market Cap
$50.11M
Enterprise Value-$10.24M
Total Cash (Recent Filing)$13.23M
Total Debt (Recent Filing)$144.93K
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Aug 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.60
Shares Outstanding33,629,555
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.19
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.36
Forecast
1Y Price Target
$13.50Price Target Upside328.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet (low Leverage)Extremely low leverage and a sizable equity base reduce near-term solvency risk and provide durable financial flexibility to support ongoing clinical programs. This standing balance-sheet strength lengthens runway options, aids negotiations with partners, and allows measured capital raises without immediate distress.
Governance Supports Financing FlexibilityShareholder approval to increase authorized shares and related governance measures creates lasting flexibility for future fundraising, equity-based collaborations or strategic transactions. That structural authorization reduces execution risk for capital raises critical to pre-revenue clinical development over the medium term.
Focused Clinical-stage R&D StrategyA clear, specialist focus on pain and neurological conditions concentrates scientific expertise and program prioritization, improving trial design and partner appeal. Over months this targeted strategy can enhance the likelihood of strategic collaborations, efficient resource allocation, and value creation if clinical signals emerge.
Bears Say
No Revenue; Widening LossesRemaining pre-revenue with materially increased net losses shifts the company's fate to successful clinical execution and external capital. Persistent, widening losses remove internal funding capacity, heighten dilution risk, and make sustained investment contingent on successful trial progress or sizable partner funding.
Persistent Negative Cash Flow And Accelerating BurnConsistent negative operating cash flow and sharply deteriorating free cash flow imply accelerating runway consumption. This structural cash-burn profile necessitates repeated external financing, increasing dilution or covenant risk, and limits strategic optionality until commercial revenue or significant partnership funding arrives.
Capital Structure Volatility From Prior FinancingHistoric swings in the balance sheet and episodic increases in debt indicate reliance on irregular financing events. That pattern creates execution risk: future financing during market stress could be more dilutive or costly, disrupting R&D timelines and potentially undermining longer-term program financing stability.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.28 and its highest was $9.50 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $50.11M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 47 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on May 14, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.043.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 33,629,555 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dogwood Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.36%
12-Months-Change
Fundamentals
Return on Equity
-35.91%
Trailing 12-Months
Asset Growth
-1.83%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$13.50
▲(328.57% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
73.57% Insiders
0.44% Mutual Funds
9.75% Other Institutional Investors
15.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---